Division of AEterna Zentaris Inc.
Latest From Zentaris GmbH
With disappointing data in advanced colorectal cancer, Keryx is expected to abandon development of the Akt pathway inhibitor and focus all efforts on Phase III candidate Zerenex in ESRD.
- Therapeutic Areas
- ZENTARIS AG
- Western Europe
- Parent & Subsidiaries
- AEterna Zentaris Inc.
- Senior Management
- Fred Sauniere, Head, Bus. Dev.
- Contact Info
Phone: (49) (69) 40 01 15 06
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.